TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: Nicotine patch plus placebo gum; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Placebo gum | Arm Label: Nicotine patch plus active gum; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Nicotine gum - Nicorette® | Intervention Type: BEHAVIORAL; Name: Cognitive Behavior Therapy for alcohol and smoking cessation; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicoderm CQ nicotine patch; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Placebo gum; Assigned to Arm(s): Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicotine gum - Nicorette®; Assigned to Arm(s): Nicotine patch plus active gum
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
C: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Bupropion SR; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: smoking cessation counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Behavioral: smoking cessation counseling | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: smoking cessation counseling; Assigned to Arm(s): Bupropion SR, Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: Smoking-cessation treatment + substance treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Smoking-cessation treatment | Arm Label: Substance-treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smoking-cessation treatment; Assigned to Arm(s): Smoking-cessation treatment + substance treatment as usual
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adderall-XR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Arm Label: Adderall-XR 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 60 mg | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 80 mg
D: Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: sustained-release bupropion (Zyban(R)); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychodynamic Model Training (R) = PDM(R); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: QA-DDS; Type: EXPERIMENTAL; Interventions: Behavioral: QA-DDS | Intervention Type: BEHAVIORAL; Name: QA-DDS; Assigned to Arm(s): QA-DDS
D: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study is to evaluate acute and long-term safety and effectiveness of Left atrial appendage occlusion (LAA)with the AtriCure LAA Occlusion System. This device will be applied in patients with atrial fibrillation (AF), paroxysmal, persistent and permanent, undergoing cardiac surgery with a concomitant Maze/Ablation procedure.


Options:
A: Arm Label: AtriCure LAA Exclusion System; Type: EXPERIMENTAL; Interventions: Device: AtriCure LAA Exclusion System | Intervention Type: DEVICE; Name: AtriCure LAA Exclusion System; Assigned to Arm(s): AtriCure LAA Exclusion System
B: Arm Label: LAA Clip; Type: EXPERIMENTAL; Interventions: Device: AtriCure LAA Exclusion System | Intervention Type: DEVICE; Name: AtriCure LAA Exclusion System; Assigned to Arm(s): LAA Clip
C: Arm Label: left atrial RF ablation groups; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Bi-atrial radiofrequency ablation group; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Amiodarone group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cardioblate® Surgical Ablation System; Assigned to Arm(s): Bi-atrial radiofrequency ablation group, left atrial RF ablation groups
D: Intervention Type: DEVICE; Name: Radiofrequency ablation; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia or Progressive Keratoconus
Brief Summary: Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.


Options:
A: Arm Label: Corneal Collagen Cross-linking (CXL) Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution, Device: UVA Irradiation | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution | Intervention Type: DRUG; Name: riboflavin ophthalmic solution; Assigned to Arm(s): Control Group, Corneal Collagen Cross-linking (CXL) Treatment Group | Intervention Type: DEVICE; Name: UVA Irradiation; Assigned to Arm(s): Corneal Collagen Cross-linking (CXL) Treatment Group
B: Arm Label: Corneal Collagen Cross-linking (CXL) Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution, Device: UVA Irradiation | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution | Intervention Type: DRUG; Name: riboflavin ophthalmic solution; Assigned to Arm(s): Control Group, Corneal Collagen Cross-linking (CXL) Treatment Group | Intervention Type: DEVICE; Name: UVA Irradiation; Assigned to Arm(s): Corneal Collagen Cross-linking (CXL) Treatment Group
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Corneal collagen | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham comparator | Intervention Type: PROCEDURE; Name: Corneal collagen; Assigned to Arm(s): Treatment | Intervention Type: PROCEDURE; Name: Sham comparator; Assigned to Arm(s): Control
D: Arm Label: total removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (total removal) | Arm Label: partial removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (partial removal) | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (total removal); Assigned to Arm(s): total removal | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (partial removal); Assigned to Arm(s): partial removal

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO
Brief Summary: A prospective multicenter study comparing patients with CRVO amd secondary macular edema treated with ranibizumab versus sham. Safety and efficacy will be evaluated. Patients will be randomized in a 1:1 ratio to one of the two arms. 32 patients, 6 months follow up. There will be monthly visits with injection the first three months and subsequently new injection if present edema.


Options:
A: Arm Label: Paclitaxel + Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, Drug: Paclitaxel | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel, Paclitaxel + Bevacizumab
B: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: C